The Rett Syndrome Research Trust (RSRT), the organization singularly focused on curing Rett syndrome, today announced 2025 research awards totaling $6.4 million, further advancing genetic medicine ...
Partnership focused on utilizing Axiomer ™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndrome Collaboration expands ProQR’s commitment to advance the ...
Rett syndrome is a rare genetic neurodevelopmental disorder that occurs primarily in females following a near normal development in the first two years of life. Rett is caused by mutations in the ...
Evox Therapeutics Ltd (“Evox” or the “Company”), a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality ...
NEW YORK and TRUMBULL, Conn., April 30, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT), ...
Rett Syndrome Research Trust Partners with Narrativa to bring AI Automation to the CURETT Initiative
Narrativa Generative AI helps to automate anything can be automated bringing clarity, proficiency, and time-savings. Narrativa and Rett Syndrome Research Trust will partner to automate portions of ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (PRQR). (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its ...
TRUMBULL, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- Rett Syndrome Research Trust (RSRT), the organization working to cure Rett syndrome, announced the launch of a bold new initiative: Roadmap to Cures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results